![]() Rakuten Medical Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies. | ![]() Blueprint Medicines Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers. | ![]() Karyopharm Therapeutics Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases. | |
Founding Date | Founding Date 2013 | Founding Date 2011 | Founding Date 2008 |
Type | Type Private | Type Public | Type Subsidiary |
Tags | |||
Locations | Locations San Diego, US HQ Setagaya City, JP Amsterdam, NL Ecublens, CH Taipei, TW Taipei, TW San Mateo, US | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH Cambridge, US | Locations Newton, US HQ München, DE Giv'atayim, IL Providence, US |
Employees | Employees 1692% decrease | Employees 38376% increase | Employees 4791% decrease |
Alexa Website Rank | Alexa Website Rank 131320 | Alexa Website Rank 182678 | Alexa Website Rank 230559 |
Employee Rating | Employee Rating 2.2 | Employee Rating 4.1 | Employee Rating 3.6 |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $793.7m (FY, 2020) | Revenue (est.) $108.1m (FY, 2020) |
Net income | Net income N/A | Net income $313.9m (FY, 2020) | Net income ($196.3m) (FY, 2020) |
Funding | |||
Total funding raised | Total funding raised $ 451.9m | Total funding raised $ 115m | Total funding raised $ 248.7m |
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
View companyKaryopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
View company